Lumos Diagnostics has secured a US$5 million milestone payment from PHASE Scientific. This infusion of cash arrives after the diagnostic test, FebriDx®, received crucial U.S. Food and Drug Administration (FDA) 510(k) clearance and a Certificate of Complexity, Waived (CLIA waiver). This regulatory green light signifies a major hurdle cleared under a distribution agreement between the two entities.
The critical achievement is the CLIA waiver, which dramatically widens the potential market for FebriDx, allowing its use in an estimated 300,000 healthcare settings across the U.S. without the need for specialized laboratory infrastructure. This expansion is key to Lumos’ strategy for broader adoption, particularly in decentralized care environments.
Market Expansion and Revenue Dependence
The recent regulatory approvals, specifically the CLIA waiver, are described as significantly broadening FebriDx’s addressable market. This now includes a vast array of U.S. locations such as primary care clinics, urgent care centers, retail clinics, pharmacies, and community health centers that possess a Certificate of Waiver. The company emphasized that the actual conversion of this milestone payment into recognized revenue hinges on the pace of incoming purchase orders from PHASE Scientific, which serves as a barometer for actual demand. Lumos is now entering a phase where execution and sales volume are paramount to its financial trajectory.
Read More: US Title X Program Changes: Birth Control Access Cut for Millions
Background: Agreement and Potential
The US$5 million payment is tied to specific conditions within a larger distribution and supply agreement signed in July 2025. This exclusive six-year deal with Hong Kong-based PHASE Scientific for U.S. distribution is valued at up to US$317 million. The agreement outlined staged payments contingent on regulatory milestones. Prior to this, Lumos had already received other payments, including an initial US$1 million exclusivity fee and a US$1 million pre-paid purchase order, with another US$1.5 million due upon the CLIA waiver application.
The FDA 510(k) clearance combined with the CLIA waiver is presented as a validation of FebriDx's clinical utility and a critical step towards widespread adoption. Lumos, an Australian-based developer of rapid, point-of-care diagnostic technologies, also offers customized assay development and manufacturing services. The successful U.S. rollout and adoption of FebriDx are critical indicators for the company’s performance.
Read More: German company Axel Springer buys Telegraph Media Group for £575 million on March 6 2026
